Phibro Animal Health reports Q2 adjusted EPS 34c, consensus 30c

Reports Q2 revenue $244.6M, two estimates $241.28M. "We were pleased with our second quarter performance. In our core business segment, Animal Health, we reported our seventh consecutive quarter of year-over-year sales growth in each of our three major product categories. On a calendar-year basis, this translates into sales growth of more than 20% in 2022 over 2020, which relative to some industry reports, puts us in the top tier of animal health companies," said Jack Bendheim, Phibro’s Chairman, President, and Chief Executive Officer.